About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics Signs Japanese License Option Agreement for TPM Oxycodone Patch

May 17, 2016

Click here to read more

Post navigation

Phosphagenics Signs Japanese License Option Agreement and R&D Alliance

Phosphagenics Expands License Agreement for Diclofenac Gel

Related Posts

Dosing Commences for CBD Topical Osteoarthritis Study

March 1, 2022March 2, 2022

Phosphagenics Provides Update on TPM Propofol Development Program

November 9, 2017

Phosphagenics Signs Non-Binding Term Sheet for Oxymorphone Patch in Japan

January 31, 2017

Recent Posts

Recruitent recommences for phase III insomnia trial
August 31, 2026
Euroz Hartleys | Successful Phase 3 Interim Results
July 8, 2026
Avecho Phase III insomnia trial advances following positive interim analysis
June 24, 2026

Categories

Analyst Coverage
Company Announcement
Company Report
Investor Webinar
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.